Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
ID: 344644Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344644

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-256.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" aimed at developing evidence-based interventions to address cancer-related health disparities among diverse populations in the United States. This initiative utilizes a phased cooperative agreement mechanism (UG3/UH3), where the initial UG3 phase focuses on refining cancer-related interventions and preparing for a pragmatic trial, followed by the UH3 phase to conduct the trial and assess its effectiveness on various cancer-related outcomes. Interested applicants, including a wide range of eligible organizations such as historically black colleges, tribal governments, and community-based organizations, must submit their applications through Grants.gov by November 17, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-256.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), is issuing an opportunity under the Pragmatic Trials across the Cancer Control Continuum program. This funding aims to develop evidence-based interventions focused on overcoming cancer-related health disparities among diverse U.S. populations. The funding mechanism is a cooperative agreement (UG3/UH3) structured in two phases: an initial UG3 phase to refine interventions and prepare for a pragmatic trial, followed by a UH3 phase to conduct the trial itself. Applications must highlight the proposed intervention’s significance, innovation, and the investigator team's qualifications. The ultimate goal is to assess the intervention's effectiveness on various cancer-related outcomes using pragmatic trial designs that reflect real-world settings. The application process involves adherence to strict guidelines and the submission of material through Grants.gov. Successful applications are expected to demonstrate strategic plans and measurable milestones to ensure effective progress and implementation of research.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.